Rheumatoid Arthritis

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

A lack of physical activity leads to a higher risk of depression among patients with rheumatic diseases.

The type of inflammatory condition may increase the risk of liver disease, despite similar treatment.

Fully understanding a patient's genes may help physicians treat rheumatic diseases.

The efficacy and safety of an adalimumab biosimilar matched the reference products in switching studies treating plaque psoriasis and rheumatoid arthritis.

The Mediterranean diet has been found to provide significant health benefits.

Adalimumab-adbm (Cyltezo) showed equivalent safety and immunogenicity to adalimumab (Humira).

Biosimilars have yet to make a significant impact on the prescription drug market.

A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.

With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.

Major adverse cardiovascular event rates for baricitinib stabilize over time.

Methotrexate discontinuation was not observed to impact rheumatoid arthritis treatment with tocilizumab, according to an abstract presented at the 2017 American College of Rheumatology Annual Meeting.

Some patients with rheumatoid arthritis require a refined treat-to-target plan.

Low incidence of 14-3-3η in patients with long-term RA, chronic HCV with arthralgias.

Flares and immune-related adverse events are common among patients with rheumatologic diseases but can often be successfully managed.

Biomarker identification may improve abatacept (Orencia) treatment for rheumatoid arthritis.

Patients with rheumatoid arthritis who switched to biologics or triple therapy had a longer time to treatment failure versus augmented oral methotrexate.

The emergence of biosimilars will reduce spending on biologics by 3% through 2027.

Two supplemental biologics license applications granted to golimumab to treat adults with psoriatic arthritis and adults with active ankylosing spondylitis.

Top news of the week from Specialty Pharmacy Times.

Many patients with rheumatoid arthritis feel their employers do not understand their condition.

Spending for adalimumab has tripled from 2012 from $4.5 billion.

Sirukumab is an anti-interleukin-6 monoclonal antibody designed to block the IL-6 pathway in a different way than currently approved IL-6 inhibitors.

Results of the case could alter the future of the biosimilar marketplace.